March 07, 2024
Alkermes Announces Appointment of Nancy S. Lurker to Board of Directors
February 15, 2024
Alkermes plc Reports Financial Results for the Fourth Quarter and Year Ended Dec. 31, 2023 and Provides Financial Expectations for 2024
January 03, 2024
Alkermes Announces Topline Results From Long-Term, Open-Label Safety and Durability of Treatment Effect Study of LYBALVI® (olanzapine and samidorpha...
Hear from Bhaskar Rege, Ph.D., as he shares his perspective on the importance of elevating the patient voice this World Sleep Day and beyond.
In celebration of International Women's Day, we asked three senior female leaders at Alkermes to reflect on their career journeys and their efforts to inspire inclusion.
Blair Jackson shares his thoughts on Alkermes' past and future as a neuroscience company.
Alkermes applies its deep neuroscience expertise to develop medicines designed to help people living with complex and difficult-to-treat psychiatric and neurological disorders. A fully-integrated, global biopharmaceutical company, with U.S. locations in Massachusetts and Ohio, and locations in Dublin and Athlone, Ireland, we seek to make a meaningful difference in the way people manage their diseases. Our patient-inspired science, integrated research strategy, sophisticated development capabilities and specialized commercial infrastructure enable us to pursue the development and commercialization of innovative new medicines, including those for people with conditions that have traditionally been overlooked or stigmatized.